Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00878124
Other study ID # CoQ10 - 08-0205-A
Secondary ID
Status Terminated
Phase N/A
First received April 7, 2009
Last updated January 11, 2010
Start date June 2009

Study information

Verified date January 2010
Source University of Toronto
Contact n/a
Is FDA regulated No
Health authority Canada: Institutional Review Board
Study type Interventional

Clinical Trial Summary

As women age the ovarian response and pregnancy rate are reduced while the rate of chromosomal abnormalities in the embryos is increased. Oocyte maturation, accurate chromosomal segregation as well as early embryo development and implantation are dependent on the supply of large amounts of energy, which unlike other cells can only arise from the mitochondria. With age the mitochondria becomes less efficient due to damage to its unique DNA, resulting in decreased energy production. The proposed study will examine the effect of the combination of a dietary supplement, Co enzyme Q10 on pregnancy rate and response of the ovaries to a medication that stimulates follicle growth. The investigators hypothesize that the improved energetic state of the oocyte would result in a more accurate chromosomal separation, increased embryo quality and pregnancy rate.


Description:

The study will be organized on an outpatient basis at the Toronto Centre for Advanced Reproductive Technology (TCART) and at the Lifequest Centre for Reproductive Medicine. The study will involve 100 women aged 38-43 years.

In the first cycle, study participants will be randomly assigned to either placebo or COQ10 capsules, (AOR - Advanced Orthomolecular Research Inc. 19 St NE Calgary, Alberta, NHPD registration codes 135307 and 113519, respectively). Study participants will take 600 mg of CoQ10 orally or identical placebo capsules for up to 5 cycles if pregnancy does not occur. All subjects will commence controlled ovarian stimulation (COH) using highly purified human menopausal gonadotropins (Menopur; Ferring Inc., North York,Ontario Canada). The starting dosage of Menopur will range from 75IU to 250 IU daily S.C. will be determined by the physician and will begin on the third day of menses, and will continue until the day prior to human chorionic gonadotropin (hCG) administration. The dosage will not be changed and must be maintained for the duration of the study. Menopur will continue daily until follicular development is considered adequate. (at least 1 follicle is >17 mm, and the E2 level is acceptable for the number of follicles present). The patient will receive an injection of hCG 250 mcg (Ovidrel, EMD Serono,Oakville, Ontario, Canada ), SC for the final stage of follicular maturation. Insemination will be by intrauterine insemination (IUI). Luteal support will consist of progesterone suppositiories 200mg (Kingsway Pharmacy,Toronto, Ontario Canada) vaginally per day starting on the day of IUI and will continue for 2 weeks until the serum beta hCG result. At the end of each cycle serum beta hCG will be drawn and if women are pregnant CoQ10/ placebo will be discontinued. If pregnant, luteal support will continue until 10 weeks gestation. If the patient is not pregnant she will have a cycle off COH but may attempt to conceive naturally. In the third cycle, COH using the same dose of Menopur as in the first cycle will be performed with IUI as in cycle one. If not pregnant, another cycle off treatment will be followed by the fifth cycle in which COH and IUI is performed..

The study endpoints will be:

1. Primary outcome measure will be pregnancy rate.

2. Secondary outcome measures will include:

- Peak estradiol level

- The number of follicles > 14 mm on day of hCG

- Number of days of stimulation / units of Menopur needed


Recruitment information / eligibility

Status Terminated
Enrollment 100
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 38 Years to 43 Years
Eligibility Inclusion Criteria:

- Each patient must meet the following criteria:

- Age 38-43 years at the time of enrollment

- Diagnosis of primary infertility

Exclusion Criteria:

- Patients must NOT have any of the following:

- Body mass index (BMI) > 38 kg/m2

- Early follicular phase (day 2-4) serum FSH level > 20 mIU/ml.

- Abnormal uterine cavity and /or tubal blockage as evidenced by sonohysterogram or hysterosalpingography

- Any current use of systemic steroid medication within 3 months of study enrollment.

- Any contraindication to being pregnant and carrying a pregnancy to term.

- Contraindication for the use of CoQ10, Menopur, hCG, and Prometrium.

- Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.

- Absence of one ovary

- Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).

- History (within past 12 months) or current abuse of alcohol or drugs.

- Administration of any investigational drugs within three months prior to study enrollment.

- Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction

- Unexplained gynecological bleeding.

- Abnormal sperm quality or semen sample inadequate for IUI preparation (TMC > 1x106 post wash)

- Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.

- Abnormal COH screening bloods for either partner, including: HIV serology, Hepatitis B and C serology, Rubella, and syphilis serology prior to participation in study.

- Unwillingness to give written informed consent.

- The concurrent use of any of the following drugs:

- CoQ10: Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Coenzyme Q10 co treatment
CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
Other:
Placebo Caps
3 caps twice a day continuously until pregnant or at the end of the study.

Locations

Country Name City State
Canada LifeQuest Centre for Reproductive Medicine Toronto Ontario
Canada Toronto center for advanced reprodutive technology Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
University of Toronto Ferring Pharmaceuticals, Toronto Centre for Advanced Reproductive Technology

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pregnancy rate Every cycle No
Secondary Peak estradiol level Every cycle No
Secondary The number of follicles > 14 mm on day of hCG Every cycle No
Secondary Number of days of stimulation/units of Menopur needed Every cycle No
See also
  Status Clinical Trial Phase
Completed NCT03433768 - Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response N/A
Recruiting NCT05601193 - Ovarian PRP Injection in Women With POR N/A
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT04013984 - Acupuncture for Treatment of Patients With Poor Ovarian Response N/A
Completed NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Completed NCT01816321 - Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial Phase 3
Recruiting NCT04310293 - Novel Therapy for Poor Responders Management N/A
Completed NCT05703308 - Menstrual Blood Stem Cells in Poor Ovarian Responders Phase 3
Not yet recruiting NCT06089395 - The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR) Early Phase 1
Completed NCT01732068 - Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol Phase 2
Completed NCT01732094 - Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders Phase 2
Recruiting NCT04717752 - A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve N/A
Recruiting NCT04024722 - Improving in Vitro Fertilization in Women With Poor Ovarian Response N/A
Completed NCT03994614 - the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR) N/A
Recruiting NCT03830697 - A Trial Study on Acupuncture Treatment of Poor Ovarian Response N/A
Recruiting NCT02801591 - Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET N/A
Recruiting NCT04273256 - Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT02993588 - Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders Phase 2/Phase 3
Terminated NCT02418572 - Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Phase 3